Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-15T19:47:15.421Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral vancomycin prophylaxis against recurrent Clostridioides difficile infection: Efficacy and side effects in two hospitals

Published online by Cambridge University Press:  16 June 2020

Ioannis M. Zacharioudakis ,
Fainareti N. Zervou ,
Yanina Dubrovskaya  and
Michael S. Phillips
Ioannis M. Zacharioudakis*
Affiliation:
Division of Infectious Diseases and Immunology, Department of Medicine, NYU School of Medicine, New York, New York
Fainareti N. Zervou
Affiliation:
Division of Infectious Diseases and Immunology, Department of Medicine, NYU School of Medicine, New York, New York
Yanina Dubrovskaya
Affiliation:
Division of Infectious Diseases and Immunology, Department of Medicine, NYU School of Medicine, New York, New York
Michael S. Phillips
Affiliation:
Division of Infectious Diseases and Immunology, Department of Medicine, NYU School of Medicine, New York, New York
*
Author for correspondence: Ioannis Zacharioudakis, E-mail: Ioannis.Zacharioudakis@nyulangone.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

The data regarding the effectiveness of chemical prophylaxis against recurrent C. difficile infection (CDI) remain conflicting.

Design:

Retrospective cohort study on the effectiveness of oral vancomycin for prevention of recurrent CDI.

Setting:

Two academic centers in New York.

Methods:

Two participating hospitals implemented an automated alert recommending oral vancomycin 125 mg twice daily in patients with CDI history scheduled to receive systemic antimicrobials. Measured outcomes included breakthrough and recurrent CDI rates, defined as CDI during and 1 month after initiation of prophylaxis, respectively. A self-controlled, before-and-after study design was employed to examine the effect of vancomycin prophylaxis on the prevalence of vancomycin-resistant Enterococcus spp (VRE) colonization and infection.

Results:

We included 264 patients in the analysis. Breakthrough CDI was identified in 17 patients (6.4%; 95% confidence interval [CI], 3.8%–10.1%) and recurrent in 22 patients (8.3%; 95% CI, 5.3%–12.3%). Among the 102 patients with a history of CDI within the 3 months preceding prophylaxis, 4 patients (3.9%; 95% CIs, 1.1%–9.7%) had breakthrough CDI and 9 had recurrent disease (8.8%; 95% CIs, 4.1%–16.1%). In the 3-month period following vancomycin prophylaxis, we detected a statistically significant increase in both the absolute number of VRE (χ2, 0.003) and the ratio of VRE to VSE isolates (χ2, 0.003) compared to the combined period of 1.5 months preceding and the 3–4.5 months following prophylaxis. This effect persisted 6 months following prophylaxis.

Conclusions:

Prophylactic vancomycin is an effective strategy to prevent CDI recurrence, but it increases the risk of VRE colonization. Thus, a careful selection of patients with high benefit-to-risk ratio is needed for the implementation of this preventive policy.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 41 , Issue 8 , August 2020 , pp. 908 - 913
Check for updates
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Magill, SS, Edwards, JR, Bamberg, W, et al.Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198–1208.CrossRefGoogle ScholarPubMed
See, I, Mu, Y, Cohen, J, et al.NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014;58:1394–1400.CrossRefGoogle ScholarPubMed
Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention website. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Published 2013. Accessed January 5, 2018.Google Scholar
Barlam, TF, Cosgrove, SE, Abbo, LM, et al.Executive summary: implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:1197–1202.CrossRefGoogle Scholar
Kenters, N, Huijskens, EGW, de Wit, SCJ, et al.Effectiveness of various cleaning and disinfectant products on Clostridium difficile spores of PCR ribotypes 010, 014 and 027. Antimicrob Resist Infect Control 2017;6:54.CrossRefGoogle ScholarPubMed
van Nood, E, Vrieze, A, Nieuwdorp, M, et al.Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407–415.CrossRefGoogle ScholarPubMed
Magill, SS, O’Leary, E, Janelle, SJ, et al.Changes in prevalence of health care-associated infections in US hospitals. N Engl J Med 2018;379:1732–1744.CrossRefGoogle Scholar
Eyre, DW, Walker, AS, Wyllie, D, et al.Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012;55 suppl 2:S77–S87.CrossRefGoogle Scholar
Deshpande, A, Pasupuleti, V, Thota, P, et al.Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015;36:452–460.CrossRefGoogle ScholarPubMed
Cornely, OA, Miller, MA, Louie, TJ, Crook, DW, Gorbach, SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012;55 suppl 2:S154–S161.CrossRefGoogle Scholar
Goldenberg, JZ, Yap, C, Lytvyn, L, et al.Probiotics for the prevention of Clostridium difficile–associated diarrhea in adults and children. Cochrane Database Syst Rev 2017;12:CD006095.Google ScholarPubMed
Kassam, Z, Lee, CH, Yuan, Y, Hunt, RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500–508.CrossRefGoogle ScholarPubMed
Prepublication requirements: new antimicrobial stewardship standard. The Joint Commision website. https://www.jointcommission.org/assets/1/6/HAP-CAH_Antimicrobial_Prepub.pdf. Published June 22, 2016. Accessed December 16, 2018.Google Scholar
Nair, S, Yadav, D, Corpuz, M, Pitchumoni, CS. Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation. Am J Gastroenterol 1998;93:1873–1876.Google Scholar
Rodriguez, S, Hernandez, MB, Tarchini, G, et al.Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. Clin Gastroenterol Hepatol 2014;12:1856–1861.CrossRefGoogle ScholarPubMed
McDonald, LC, Gerding, DN, Johnson, S, et al.Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018.CrossRefGoogle Scholar
Van Hise, NW, Bryant, AM, Hennessey, EK, Crannage, AJ, Khoury, JA, Manian, FA. Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis 2016;63:651–653.CrossRefGoogle ScholarPubMed
Carignan, A, Poulin, S, Martin, P, et al.Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol 2016;111:1834–1840.CrossRefGoogle ScholarPubMed
Splinter, LE, Kerstenetzky, L, Jorgenson, MR, et al.Vancomycin prophylaxis for prevention of Clostridium difficile infection recurrence in renal transplant patients. Ann Pharmacother 2018;52:113–119.CrossRefGoogle ScholarPubMed
Ganetsky, A, Han, JH, Hughes, ME, et al.Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis 2019;68:2003–2009.CrossRefGoogle ScholarPubMed
Shenoy, ES, Paras, ML, Noubary, F, Walensky, RP, Hooper, DC. Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infect Dis 2014;14:177.CrossRefGoogle ScholarPubMed
O’Driscoll, T, Crank, CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 2015;8:217–230.Google ScholarPubMed
Al-Nassir, WN, Sethi, AK, Li, Y, Pultz, MJ, Riggs, MM, Donskey, CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403–2406.CrossRefGoogle ScholarPubMed